Life Sciences Forum 2021

Anna Dwyer

counsel, Weil Gotshal & Manges

Anna Dwyer is counsel in the Patent Litigation practice group in Weil’s New York office. She practices complex Hatch-Waxman litigation with an emphasis on the chemical and pharmaceutical arts. She has experience with every stage of litigation, from initial investigation and pleadings, through discovery, Markman, motion practice, trial, and appeal.

 Speaking session 

Exploring the realities of updated S.101 guidance

Wednesday, June 16 - 12.20 - 1.10 EST

Guillaume Stern

director, patent counsel – global medical devices and digital health, Teva

Guillaume started his career as M&A analyst for a telecommunication company. He worked in China as Sales and Training engineer in the field of infrared systems. In 2007, he then focused his career on Intellectual Property and worked for leading IP law firms in France and Israel. Since 2015, Guillaume joined the Swiss branch of the Teva group, the largest generic drug manufacturer. In my current practice, and focuses on counselling Teva Medical Devices and Digital Health teams on IP matters in particular for protecting their inventions, ensuring favorable contractual relationships with third parties and designing around relevant IP rights.”

 Speaking session 

Exploring the realities of updated S.101 guidance

Wednesday, June 16 - 12.20 - 1.10 EST

Bonnie Nannenga-Combs

director, Sterne Kessler Goldstein & Fox

TBC

 Speaking session 

Focus sessions

Thursday, June 17 - 12.20 - 1.10 EST

John Covert

director, Sterne Kessler Goldstein & Fox

TBC

 Speaking session 

Focus sessions

Thursday, June 17 - 12.20 - 1.10 EST

Jenny Antcliff

partner, Carpmaels & Ransford

TBC

 Speaking session 

Focus sessions

Thursday, June 17 - 12.20 - 1.10 EST

Simon Llewellyn

partner, Carpmaels & Ransford

TBC

 Speaking session 

Focus sessions

Thursday, June 17 - 12.20 - 1.10 EST

Christina Schwarz

partner, Venable

Christina Schwarz is a pharmaceutical and biotechnology patent litigator who focuses on complex litigation and contested proceedings. Christina has argued before the federal district courts, the U.S. Court of Appeals for the Federal Circuit, and the Patent Trial and Appeal Board (PTAB). She also frequently counsels clients on litigation and non-litigation matters, and conducts pre-lawsuit investigations. Her work covers a wide range of products and technologies, including drugs and treatments for numerous cancers and non-malignant tumors, immunosuppression, HCV, renal disease, Pompe disease, schizophrenia, drug formulations, drug delivery devices, and polymers.

 Speaking session 

Litigation case law developments – evolution of the PTAB

Wednesday, June 16 - 1.40 - 2.30 EST

Whitney Meier

counsel, Venable

Whitney Meier's practice focuses on complex patent litigation and contested proceedings before the United States Patent Office with an emphasis in pharmaceuticals and biotechnology. Whitney litigation and counseling experience cover a range of technologies, including chemotherapies, bisphosphonates, antipsychotics, small molecule formulation, genetically modified mice, and antibody manufacturing. Whitney's practice also includes many aspects of trademark law, including clearing and prosecuting U.S. and foreign trademarks.

 Speaking session 

Litigation case law developments – evolution of the PTAB

Wednesday, June 16 - 1.40 - 2.30 EST

Francesco Macchetta

strategic IP advisor, Bracco

TBC

 Speaking session 

Responding to the IP waiver for COVID vaccines

Wednesday, June 16 - 11.10 - 12.00 EST

Karen Moreira

director, IP litigation, Merck

Karen Moreira is a Director in the Intellectual Property Litigation group at Merck Sharp & Dohme Corp. At Merck, Karen is responsible for coordinating and managing all aspects of global intellectual property litigation. Her experience ranges from traditional and Hatch-Waxman lawsuits, post-grant review proceedings, including inter partes reviews, foreign infringement actions and parallel nullity proceedings, trademark disputes, and appeals. Karen most recently spent a year on a rotation project, working on product liability, cyberspace, and contract disputes.

Before Merck, Karen was an associate at a boutique patent litigation firm in New York City, and prior to that, she conducted research in medicinal chemistry at Bristol-Myers Squibb in the field of oncology. Karen was involved in the creation of WIN, a network comprised of East Coast professional women in IP law. Karen participates in the Hope for Veterans pro bono program at the New Jersey Community Hope Center. Outside of the office, she serves on the Board of Directors of MAESSR, a non-profit volunteer organization devoted to the rescue of English Springer Spaniels. She also volunteers at the Monmouth County SPCA. Karen has a J.D. from the University of Connecticut, M.S. in chemistry from Duke University, and a B.S. in chemistry from Wake Forest University.

 Speaking session 

Exploring the realities of updated S.101 guidance

Wednesday, June 16 - 12.20 - 1.10 EST

Paul Coletti

associate patent counsel, Johnson & Johnson

TBC.

 Speaking session 

Global protection and enforcement strategies

Wednesday, June 16 - 3.00 - 3.50 EST

Ewan Nettleton

principal IP counsel, oncology litigation, Novartis

Ewan is Principal IP Counsel, Oncology Litigation at Novartis Pharma AG in Switzerland where he works on global pharmaceutical litigation co-ordination projects. This involves managing IP and related litigation projects in a wide range of jurisdictions. Ewan is a qualified UK solicitor (since September 2002), and has an MA in chemistry and a DPhil in protein chemistry from Balliol College, Oxford as well as a Diploma in Intellectual Property Law and Practice from Bristol University and a CEIPI Patent Litigation in Europe Diploma from the University of Strasbourg. He is also a member of the Royal Society of Chemistry and the Chartered Institute of Patent Attorneys. Prior to joining Novartis in September 2010, Ewan was an associate at Bristows LLP in London specializing in IP law with an emphasis on litigation. In addition to his IP expertise, Ewan’s experience also extends to regulatory law and related exclusivities, antitrust law, customs seizures, and to medical devices and IT matters.

 Speaking session 

Focus sessions

Thursday, June 17 - 12.20 - 1.10 EST

Jiang Lin

principal counsel, global patent litigation , Sanofi

Jiang Lin is Principal Counsel, Global Patent Litigation at Sanofi where she coordinates and manages pharmaceutical and biotechnology patent litigation projects across a wide range of jurisdictions. Ms. Lin has an M.S. in organic chemistry from The Ohio State University. She started working for Sanofi predecessor companies as a research chemist before earning her law degree magna cum laude from Seton Hall University School of Law. Ms. Lin has extensive patent experience in her more than 20 years at Sanofi including drafting and prosecuting patent applications, patent litigation, contested patent office proceedings, and appeals, all on a global scale.

 Speaking session 

Litigation case law developments – evolution of the PTAB

Wednesday, June 16 - 1.40 - 2.30 EST

Kim Moore

vice president, legal, Guardant Health

TBC

Before Merck, Karen was an associate at a boutique patent litigation firm in New York City, and prior to that, she conducted research in medicinal chemistry at Bristol-Myers Squibb in the field of oncology. Karen was involved in the creation of WIN, a network comprised of East Coast professional women in IP law. Karen participates in the Hope for Veterans pro bono program at the New Jersey Community Hope Center. Outside of the office, she serves on the Board of Directors of MAESSR, a non-profit volunteer organization devoted to the rescue of English Springer Spaniels. She also volunteers at the Monmouth County SPCA. Karen has a J.D. from the University of Connecticut, M.S. in chemistry from Duke University, and a B.S. in chemistry from Wake Forest University.

 Speaking session 

Exploring the realities of updated S.101 guidance

Wednesday, June 16 - 12.20 - 1.10 EST

Jesse Fecker

global legal advisor, Ferring Pharmaceuticals

TBC.

 Speaking session 

Global protection and enforcement strategies

Wednesday, June 16 - 3.00 - 3.50 EST

Noah Leibowitz

partner, Dechert

TBC.

 Speaking session 

Litigation case law developments – Federal Circuit and District Court

Thursday, June 17 - 11.10 - 12.00 EST

Sharon Gagliardi

counsel, Dechert

TBC.

 Speaking session 

Litigation case law developments – Federal Circuit and District Court

Thursday, June 17 - 11.10 - 12.00 EST

Jacequline Bonilla

deputy chief admistrative patent judge, PTAB, USPTO

The Honorable Jacqueline Wright Bonilla serves as Deputy Chief Administrative Patent Judge at the Patent Trial and Appeal Board (PTAB) at the U.S. Patent and Trademark Office. Since her appointment as an Administrative Patent Judge in January 2012, she has conducted numerous post-grant patent trials under the America Invents Act, heard appeals from adverse examiner decisions in patent applications and reexamination proceedings, and rendered decisions in interferences. In her current role, she helps lead the PTAB as it handles cases and renders decisions in all areas of its jurisdiction. Previously, she worked for twelve years in private practice, including as a partner at Foley & Lardner, LLP. She also served as a judicial law clerk to the now-retired Chief Judge Randall Rader at the U.S. Court of Appeals for the Federal Circuit. Judge Bonilla graduated from the University Of Virginia School Of Law, and holds a Ph.D. in Pharmacology from the University of Virginia, and a B.A. in Biochemistry from the University of California, Berkeley.

 Speaking session 

Litigation case law developments – evolution of the PTAB

Wednesday, June 16 - 1.40 - 2.30 EST

Erick Pereira Stegun

IP specialist, Brazil,

TBC

TBC

 Speaking session 

Patent validity terms in Brazil

Thursday, June 17 - 1.40 - 2.35 EST

Paul Fehlner

SVP, chief legal officer and corporate secretary, Axcella

TBC.

 Speaking session 

Responding to the IP waiver for COVID vaccines

Wednesday, June 16 - 11.10 - 12.00 EST

James Evans

director, dispute resolution, Regeneron Pharmaceuticals

Dr. Evans (“James”) is Director, Dispute Resolution at Regeneron Pharmaceuticals where he works on strategies for global pharmaceutical litigations, including disputes before U.S. district courts, the United States Patent and Trademark Office (“USPTO”), and European courts. James’s litigation experience covers a range of technologies, including biologics, small molecules, formulations, antibody manufacturing, genetically modified mice, vector constructs, and devices. He earned a Ph.D. in immunology from Yale University and a law degree with honors and a special certificate in intellectual property law with highest honors from Quinnipiac University. Prior to joining Regeneron in October 2019, James was counsel at King & Spalding and prior to that was an associate at Paul Hastings where he specialized in ANDA litigations and matters concerning biologics, including infringement litigations, Biologics Price Competition and Innovation (“BPCIA”) litigations and strategies, and inter partes reviews (“IPRs”).

 Speaking session 

Litigation case law developments – Federal Circuit and District Court

Thursday, June 17 - 11.10 - 12.00 EST

Constantin Rehaag

partner, Dentons

Dr. Constantin Rehaag, MA, is a partner in Dentons' Frankfurt office. Since 2005 he specialises in intellectual property and unfair competition law, in particular trademarks, designs and copyright law. Constantin has comprehensive experience in IP litigation including patent litigation, in advising on and negotiating license and IT agreements, in registration and in anti-counterfeiting work as well as related criminal law. He also advises clients on data protection law.

His comprehensive sector experience covers the following industries: pharma, air transportation, luxury goods and fashion, automotive, music and publishing, printing and office machinery, forestry and construction, drinks and tobacco as well as logistics.

Constantin regularly publishes articles on intellectual property law and is a lecturer-in-law at the University of Passau.

 Speaking session 

Global protection and enforcement strategies

Wednesday, June 16 - 3.00 - 3.50 EST

Loïc Lemercier

partner, Dentons

Loïc Lemercier, Partner, heads the Intellectual Property and Technologies (IP&T) group of Dentons’ Paris office.

Over the last 10 years, Loïc has handled both contentious and non-contentious patent, trademark, copyright, design, unfair competition and trade secret cases.

Focusing on industrial property, Loïc has built a solid patent litigation track record assisting many large corporations with a particular emphasis on the pharmaceutical and telecoms sectors. Loïc's practice includes initiating and defending preliminary injunction proceedings, seizures for gathering evidence, and actions on the merits dealing with validity and/or infringement of the intellectual property rights.

Loïc regularly advises clients in the technology sector, particularly in relation to FRAND obligations and the impact of those obligations on obtaining relief in France.

In addition to his litigation work, Loïc advises his clients on contract negotiation and drafting (e.g. R&D, trademark or patent licensing, pledge agreement) in the context of M&A transactions.

 Speaking session 

Global protection and enforcement strategies

Wednesday, June 16 - 3.00 - 3.50 EST

Komal Kalha

associate director, intellectual property & trade policy, IFPMA

TBC.

 Speaking session 

Responding to the IP waiver for COVID vaccines

Wednesday, June 16 - 11.10 - 12.00 EST

Ricardo Nunes

partner, Daniel Law

TBC

TBC

 Speaking session 

Patent validity terms in Brazil

Thursday, June 17 - 1.40 - 2.35 EST

Matthew Blischak

partner, intellectual property, Roivant Sciences

TBC

 Speaking session 

Focus sessions

Thursday, June 17 - 12.20 - 1.10 EST